Scarica l'app Stockscreener
8.94
3.71%
0.32
Dopo l'orario di chiusura:
8.92
-0.02
-0.22%
Precedente Chiudi:
$8.62
Aprire:
$8.5
Volume 24 ore:
418.13K
Relative Volume:
0.47
Capitalizzazione di mercato:
$473.50M
Reddito:
-
Utile/perdita netta:
$-29.44M
Rapporto P/E:
-10.04
EPS:
-0.8906
Flusso di cassa netto:
$-24.66M
1 W Prestazione:
+2.52%
1M Prestazione:
+6.94%
6M Prestazione:
+325.71%
1 anno Prestazione:
+441.82%
Intervallo 1D:
$8.40
$9.28
Intervallo di 1 settimana:
$8.00
$9.60
Portata 52W:
$1.34
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.94 | 473.50M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-09 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-09 | Iniziato | Mizuho | Outperform |
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - intellectia.ai
Immix Biopharma — Momentum builds with NEXICART-2 progress - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com Australia
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - TipRanks
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - Stock Titan
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - National Today
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - MarketScreener
Immix Biopharma completes enrollment in AL amyloidosis trial - Investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - Investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - minichart.com.sg
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - Investing.com South Africa
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 By Investing.com - Investing.com India
Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 - Investing.com
Citizens reiterates Immix Biopharma stock rating on drug progress By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on drug progress - investing.com
Immix Biopharma (NASDAQ:IMMX) Now Covered by Morgan Stanley - Defense World
Immix Biopharma, Inc. Files Form 8-K Announcing Amendment to ATM Agreement and Legal Opinion – March 25, 2026 - minichart.com.sg
Immix Biopharma, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma’s NXC-201: Next-Generation CAR-T Therapy for AL Amyloidosis and Other Serious Diseases – Pipeline, Strategy, and Clinical Advances - minichart.com.sg
Millennium Management LLC Acquires Significant Stake in Immix Bi - GuruFocus
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):